You are here: Industry Insights > therapy

News List

Light Therapy May Prevent Oral Mucositis for Some in Cancer Tx drugs
July 23, 2019
Photobiomodulation (PBM), such as laser and other light therapies, is recommended for prevention of oral mucositis (OM) in specific populations of cancer patients...
Hurricanes Can Hurt Survival Odds Among Those With Cancer drugs
July 17, 2019
When a hurricane strikes, as tropical storm Barry did this weekend in Louisiana, most people worry about the immediate health dangers such a storm poses.
FDA grants Fast Track Designation to Parkinson’s therapy europeanpharmaceuticalreview
July 12, 2019
PR001 has received Fast Track Designation from the regulatory body for the treatment of Parkinson’s disease.
Passage Bio Announces New Gene Therapy Manufacturing Suite contractpharma
July 11, 2019
Dedicated cGMP suite to be built under partnership agreement with Paragon Gene Therapy .
ISTH Announces Launch Of New Global Education Initiative In Gene Therapy For Hemophilia prnasia
July 08, 2019
The International Society on Thrombosis and Haemostasis (ISTH) is pleased to announce the official launch of Gene Therapy in Hemophilia: An ISTH Education Initiative.
Amicus, Catalent Biologics Enter Gene Therapy Mfg. Pact contractpharma
July 03, 2019
Will support clinical and commercial supply needs for Pompe and other Lysosomal Disease Gene Therapy Programs.
PTC Therapeutics, Odylia Therapeutics Enter Gene Therapy Alliance contractpharma
July 03, 2019
Expands PTC's gene therapy portfolio to rare ophthalmic diseases .
Combination Therapy for Rosacea Shows Improved Response Rates drugs
June 27, 2019
Combination Therapy for Rosacea Shows Improved Response Rates.
Axovant, Yposkesi Ink Gene Therapy Pact contractpharma
June 21, 2019
CDMO to support the global development and commercialization of Axovant’s gene therapy programs.
Voyager Therapeutics, Sanofi Genzyme Restructure Gene Therapy Alliance contractpharma
June 18, 2019
Voyager gains worldwide rights to VY-HTT01 Huntington’s disease program and ex-U.S. rights to VY-FXN01 Friedreich’s ataxia program for $10 million upfront.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 Next page